VISTA, Calif. , Nov. 1, 2024 /PRNewswire/ -- Leica Biosystems, a global leader in anatomic pathology, today announced non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, to accelerate the usage of DICOM and standardization in Digital Pathology.
DICOM usage in digital pathology is on the rise, paving the way for enhanced interoperability through the standardization of storing, transmitting, and sharing whole slide images and associated data. This growth is not just a technical advancement; it represents a tremendous opportunity to improve patient care and streamline workflows for healthcare professionals. Leica Biosystems Aperio Digital Pathology solutions have pioneered DICOM standardization since the formation of Working Group 26 in 2005.
The company has played a key role in this journey, particularly with the Aperio GT 450 DX, which became the first digital pathology system to receive FDA 510(k) clearance using DICOM format. This achievement underscores the company's commitment to innovation and leadership in the field. In the spirit of collaboration and progress, Leica Biosystems is pleased to announce non-enforcement of its DICOM patent portfolio by no longer requiring a patent licence agreement.
This next step empowers companies to optimize and utilize this essential standard without the constraints of patent licensing from Leica Biosystems. By removing these barriers, the company hopes to foster greater inn.